Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Cullinan's Velinotamig Reduces Disease Activity in 8 of 9 Evaluable Patients in Early Lupus Study

By Public Technologies
  • Cullinan Therapeutics announced early results from Genrix Bio’s Phase 1b/2a velinotamig trial in patients with refractory systemic lupus erythematosus.
  • Results will be presented at ACR Convergence 2026 on November 8; 12 patients had received treatment by September 8.
  • Eight of nine evaluable patients showed clinically meaningful improvement in disease activity.
  • Five of seven patients with elevated urinary protein showed marked reductions; four achieved complete renal responses within 24 weeks.
  • No dose-limiting toxicities or severe cytokine release syndrome occurred; two patients experienced mild or moderate cytokine release syndrome that resolved with treatment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-452644), on November 09, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.